Yantai Zhenghai Biotechnology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Yantai Zhenghai Biotechnology (SZSE:300653) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥413.7m (down 4.5% from FY 2022).
• Net income: CN¥191.0m (up 3.0% from FY 2022).
• Profit margin: 46% (up from 43% in FY 2022). The increase in margin was driven by lower expenses.
• EPS: CN¥1.06.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Yantai Zhenghai Biotechnology EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) exceeded analyst estimates by 1.4%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 2.6% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Yantai Zhenghai Biotechnology, and understanding this should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.